Charles Schwab’s Theriva Biologics TOVX Stock Holding History

Charles Schwab’s Portfolio TOVX Stock Details TOVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-543	Closed	-$6.36K	–	3681
2024 Q1	$6.36K	Hold	543	–	–	﹤0.01%	3469
2023 Q4	$5.83K	Hold	543	–	–	﹤0.01%	3536
2023 Q3	$7.32K	Hold	543	–	–	﹤0.01%	3571
2023 Q2	$13.6K	Hold	543	–	–	﹤0.01%	3587
2023 Q1	$9.47K	Hold	543	–	–	﹤0.01%	3540
2022 Q4	$6.17K	Hold	543	–	–	﹤0.01%	3542
2022 Q3	$14K	Hold	543	–	–	﹤0.01%	3497
2022 Q2	$29K	Buy	+543	New	+$31.1K	﹤0.01%	3481
2021 Q2	–	Sell	-209	Closed	-$36K	–	3537
2021 Q1	$36K	Buy	+209	New	+$41.3K	﹤0.01%	3473
2017 Q2	–	Sell	-13	Closed	-$75K	–	3136
2017 Q1	$75K	Hold	13	–	–	﹤0.01%	3030
2016 Q4	$91K	Hold	13	–	–	﹤0.01%	3047
2016 Q3	$204K	Hold	13	–	–	﹤0.01%	2916
2016 Q2	$213K	Buy	+13	New	+$245K	﹤0.01%	2916

Other funds holding TOVX

MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return

Charles Schwab's TOVX Position: Q2 2024 in Review

Charles Schwab sold out of Theriva Biologics (TOVX) in Q2 2024, closing a stake of 543 shares — an estimated $6.36K sold.

Charles Schwab first reported a position in TOVX in Q2 2016 and held it in 13 quarters. The position peaked at $213K in Q2 2016. 20 funds tracked by Wall St. Rank hold TOVX as of Q2 2024.

Charles Schwab reported no remaining Theriva Biologics position as of Q2 2024 after selling out during the quarter.
Charles Schwab sold 543 Theriva Biologics shares in Q2 2024, an estimated $6.36K.
Charles Schwab first reported a position in Theriva Biologics in Q2 2016 and held it in 13 quarters.
Charles Schwab's Theriva Biologics position peaked at $213K in Q2 2016.
20 funds tracked by Wall St. Rank held Theriva Biologics as of Q2 2024.

Based on Charles Schwab's 13F filing for Q2 2024, filed 12 Aug 2024.